Abstract
Introduction
Since early 2020 the whole world has been challenged by the SARS-CoV-2 virus and the associated global pandemic (Covid-19). People with diabetes are particularly at high risk of becoming seriously unwell after contracting this virus.
Methods
This population-based study included people living in the Greater Manchester conurbation who had a recorded diagnosis of type 1 diabetes mellitus (T1DM) or type 2 diabetes mellitus (T2DM) and subsequent Covid-19 infection. Each individual with T1DM (n = 862) or T2DM (n = 13,225) was matched with three Covid-19-infected non-diabetes controls.
Results
For individuals with T1DM, hospital admission rate in the first 28 days after a positive Covid-19 test was 10% vs 4.7% in age/gender-matched controls [relative risk (RR) 2.1]. For individuals with T2DM, hospital admission rate after a positive Covid-19 test was 16.3% vs 11.6% in age/gender-matched controls (RR 1.4). The average Townsend score was higher in T2DM (1.8) vs matched controls (0.4), with a higher proportion of people with T2DM observed in the top two quintiles of greatest disadvantage (p < 0.001). For Covid-19-infected individuals with T1DM, factors influencing admission likelihood included age, body mass index (BMI), hypertension, HbA1c, low HDL-cholesterol, lower estimated glomerular filtration rate (eGFR), chronic obstructive pulmonary disease (COPD) and being of African/mixed ethnicity. In Covid-19-infected individuals with T2DM, factors related to a higher admission rate included age, Townsend index, comorbidity with COPD/asthma and severe mental illness (SMI), lower eGFR. Metformin prescription lowered the likelihood. For multivariate analysis in combined individuals with T2DM/controls, factors relating to higher likelihood of admission were having T2DM/age/male gender/diagnosed COPD/diagnosed hypertension/social deprivation (higher Townsend index) and non-white ethnicity (all groups).
Conclusion
In a UK population we have confirmed a significantly higher likelihood of admission in people with diabetes following Covid-19 infection. A number of factors mediate that increased likelihood of hospital admission. For T2DM, the majority of factors related to increased admission rate are common to the general population but more prevalent in T2DM. There was a protective effect of metformin in people with T2DM.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details
1 The University of Manchester, The School of Medicine and Manchester Academic Health Sciences Centre, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407); The University of Manchester, Department of Diabetes and Endocrinology, Salford Royal NHS Foundation Trust, Salford, The School of Medicine and Manchester Academic Health Sciences Centre, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
2 University of Manchester, Manchester Academic Health Science Centre, Division of Informatics, Imaging and Data Science, Faculty of Biology, Medicine and Health, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407); The University of Manchester, NIHR Greater Manchester Patient Safety Translational Research Centre, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
3 The University of Manchester, Department of Diabetes and Endocrinology, Salford Royal NHS Foundation Trust, Salford, The School of Medicine and Manchester Academic Health Sciences Centre, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
4 Manchester Metropolitan University, Department of Sport and Exercise Sciences, Musculoskeletal Science and Sports Medicine Research Centre, Manchester, UK (GRID:grid.25627.34) (ISNI:0000 0001 0790 5329)
5 University of the West Indies, Cavehill Campus, Barbados (GRID:grid.412886.1) (ISNI:0000 0004 0592 769X); University of Manchester, Division of Cardiovascular Sciences, Faculty of Biology Medicine and Health, Manchester, UK (GRID:grid.5379.8) (ISNI:0000000121662407)
6 Manchester Metropolitan University, Faculty of Science and Engineering, Manchester, UK (GRID:grid.25627.34) (ISNI:0000 0001 0790 5329)





